HIV-1-infection
Conditions
Keywords
UB-421, HIV
Brief summary
* To assess the impact of UB-421 and chidamide in changing HIV-1 viral reservoir profile among HIV-1 suppressed patients who undergo short-term ART interruption. * To evaluate the safety and tolerability of UB-421 combined with chidamide among HIV-1 suppressed patients who undergo short-term ART interruption.
Interventions
BIOLOGICALUB-421
10mg/kg weekly intravenous infusion to substitute for for antiretroviral therapy
OTHERUB-421+chidamide
10 mg/kg UB-421 weekly intravenous infusion to substitute for antiretroviral therapy, and combined with oral 10 mg chidamide twice a week for 8 weeks. Chidamide taken on the one day and three days after the administration of UB-421.
Sponsors
UBP Greater China (Shanghai) Co., Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Subjects are eligible to be included in the study only if ALL of the following criteria apply: 1. HIV-1 sero-positive, with documented HIV-1 infection by official, signed, written history. 2. Male with body weight ≥ 50 kg or female with body weight ≥ 45 kg, aged 18 years or older. 3. Have been receiving at least (≧) 2 nucleoside/ nucleotide reverse transcriptase inhibitors (NRTI) plus one non-nucleoside reverse transcriptase inhibitor (NNRTI), protease inhibitor (PI, either boosted or un-boosted), integrase strand transfer inhibitor (INSTI) or entry inhibitor (EI) for more than 1 years. 4. Have more than 2 different alternative options of optimized ART regimen. 5. HIV-1 plasma viral load (VL) level well suppressed below 50 RNA copies/mL for at least (≧) 12 months. 6. No breastfeeding or pregnancy for women. 7. Both male and female patients and their partners of childbearing potential must agree to use 2 medically accepted methods of contraception (eg, barrier contraceptives \[male condom, female condom, or diaphragm with a spermicidal gel\], hormonal contraceptives \[implants, injectable, combinational oral contraceptives, transdermal patches, or contraceptive rings\], and intrauterine devices) during the course of the study (excluding women who are not of childbearing potential and men who have been sterilized). Females of childbearing potential must have a negative serum pregnancy test. 8. Subjects must sign the informed consent before undergoing any study procedures.
Exclusion criteria
Subjects meeting ANY of the following criteria will be excluded from the study: 1. Subjects with active systemic infections, except for HIV-1, that the investigator feels the infections may confound evaluation and treatment for HIV-1. 2. Any acquired AIDS-defining illness such as non-Hodgkin's lymphoma or Kaposi's sarcoma according to the U.S. Centers for Disease Control and Prevention Classification System for HIV-1 Infection within the past 12 months . 3. Any documented CD4+ T cell count \< 200 cells/mm3 within the past 12 weeks . 4. Any exposure to a monoclonal antibody within the past 12 weeks. 5. Any significant diseases (other than HIV-1 infection) or clinically significant findings, that, in the Investigator's opinion, would preclude the subject from well participation or confound the assessment of study objectives. 6. Current receiving treatment regimen for Diabetes, hepatitis B, hepatitis C, or latent tuberculosis. 7. History of anaphylaxis to any monoclonal antibodies or HDAC inhibitor agents. 8. Received blood transfusion or hematopoietic growth factor treatment, any vaccine, or a compound with HDAC inhibitor activity (such as valproic acid) recently. 9. Use of immunomodulators, HIV vaccine, or systemic chemotherapy within 180 days prior to V1. 10. More than one change of ART regimen because of the inability to achieve or maintain suppression of viral replication to an HIV-1 RNA level \< 200 copies/mL within the past 12 months 11. Receipt of any other investigational study agent(s) within 90 days. 12. Experienced urticaria in recent 6 months or ongoing or unresolved skin problems with rash-like symptoms .
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| HIV-1 Total DNA levels | Post-treatment weeks up to 48 weeks | The change in HIV-1 Total DNA from baseline after the study drug administration. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| HIV-1 Total DNA levels | Post-treatment weeks up to 48 weeks | The changes in HIV-1 Total DNA levels during the study |
| Treatment related TEAE | through study completion, an average of 0.5 year | The incidence of Grade 3 or higher grade drug-related treatment-emergent adverse events (TEAE) |
| Viral suppression | Post-treatment weeks up to 48 weeks | Descriptive analysis of loss of viral suppression (HIV-1 VL\> 50 copies/ml) during the study period. |
| The number of adverse subjects | Post-treatment weeks up to 48 weeks | The number of adverse subjects leading to discontinuation of UB 421 or Chidamide. |
Contacts
Primary ContactLinda Shih, MSc
Outcome results
None listed